Retagliptin Phosphate
CAS: 1256756-88-3
Ref. 3D-GAC75688
5mg | Discontinued | ||
10mg | Discontinued | ||
25mg | Discontinued | ||
50mg | Discontinued | ||
100mg | Discontinued |
Product Information
Retagliptin is a dipeptidyl peptidase-4 inhibitor that is used to treat type 2 diabetes. It inhibits the action of dipeptidyl peptidase-4 (DPP-4) in the pancreas and blocks the breakdown of incretin hormones, such as glucagon-like peptide 1 (GLP-1). Retagliptin has a dose-dependent pharmacokinetic profile and is metabolized by both liver and intestinal enzymes. It also undergoes renal elimination, with about 40 percent excreted unchanged in urine. The most common side effects include low blood pressure, diarrhea, nausea, dizziness, headache, and vomiting. Retagliptin has been shown to have toxicokinetics parameters similar to those of animals.